BioCentury
ARTICLE | Company News

Qiagen, British Columbia Cancer Agency, Columbia University deal

June 10, 2013 7:00 AM UTC

Qiagen entered two exclusive license agreements for cancer biomarkers that the company plans to use to develop diagnostics. The company licensed worldwide rights from the university to fibroblast growth factor (FGF) receptor ( FGFR)-transforming acidic coiled-coil containing protein (TACC) fusion genes, which Qiagen intends to develop for glioblastoma and other cancers. Qiagen also licensed lymphoma-related biomarkers, including the enhancer of zeste homolog 2 (EZH2) Y641 mutation, from the agency. The company said the EZH2 Y641 mutation may be developed into a companion diagnostic to identify patients that could benefit from EZH2-targeted therapies. Qiagen could not be reached for details. ...